



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Neuropeptide Y Receptor

NPY receptor



Neuropeptide Y receptors belong G protein-coupled receptor superfamily and comprise various subtypes. There are currently five cloned NPY receptor subtypes in mammals, termed Y1, Y2, Y4, Y5, and Y6. Neuropeptide Y receptors mediate a variety of physiological responses including feeding and vasoconstriction.











Subtypes Y1, Y2, Y4 and Y5 are expressed in humans. They are present mainly in the central and peripheral nervous systems as well as other tissues, such as the cardiovascular system. Their physiologic ligands are the neurotransmitter Neuropeptide Y and the 2 hormones peptide YY (PYY) and pancreatic polypeptide (PP).




Neuropeptide Y and its receptors regulate important biological and pathophysiological functions, such as blood pressure, neuroendocrine secretions, seizures, neuronal excitability and neuroplasticity.


Neuropeptide Y Receptor Agonists, Antagonists, Inhibitors & Modulators






<p>(R)-JNJ-31020028</p> <p>Cat. No.: HY-107479</p> <p>(R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC₅₀ values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BIBO3304 TFA</p> <p>Cat. No.: HY-107725</p> <p>BIBO3304 TFA is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC₅₀=0.38 and 0.72 nM, respectively).</p> <p>Purity: 99.95% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>BIBP3226</p> <p>Cat. No.: HY-107726A</p> <p>BIBP3226 is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with K_s of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 displays anxiogenic-like effect.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BIBP3226 TFA</p> <p>Cat. No.: HY-107726</p> <p>BIBP3226 TFA is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with K_s of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 TFA displays anxiogenic-like effect.</p> <p>Purity: 98.09% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg</p>
<p>BIIE-0246 (AR-H 053591)</p> <p>Cat. No.: HY-101986</p> <p>BIIE-0246 is a potent and highly selective non-peptide neuropeptide Y (NPY) Y₂ receptor antagonist, with an IC₅₀ of 15 nM.</p> <p>Purity: ≥99.0% Clinical Data: No Development Reported Size: 1 mg</p>	<p>BMS-193885</p> <p>Cat. No.: HY-120619</p> <p>BMS-193885 is a potent, selective, competitive, and brain penetrant neuropeptide Y₁ receptor antagonist with a K_i of 3.3 nM, and has an IC₅₀ of 5.9 nM for hY₁, which displays > 100, > 160, > 160 and > 160-fold selectivity over α₁, hY₂, hY₄ and hY₅ receptors, respectively.</p> <p>Purity: 99.08% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg</p>
<p>CART(55-102)(human) TFA</p> <p>Cat. No.: HY-P1304A</p> <p>CART(55-102)(human) TFA is a human satiety factor with potent appetite-suppressing activity. CART(55-102)(human) TFA is closely associated with leptin and neuropeptide Y.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CART(55-102)(rat) TFA</p> <p>Cat. No.: HY-P1305A</p> <p>CART(55-102)(rat) TFA is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) TFA is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) TFA can induces anxiety and stress-related behavior.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CGP71683 hydrochloride (CGP71683A)</p> <p>Cat. No.: HY-107723</p> <p>CGP71683 hydrochloride is a competitive neuropeptide Y5 receptor antagonist with a K_i of 1.3 nM, and shows no obvious activity at Y1 receptor (K_i >4000 nM) and Y2 receptor (K_i 200 nM) in cell membranes.</p> <p>Purity: 99.12% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>CYM 9484</p> <p>Cat. No.: HY-107735</p> <p>CYM 9484 is a selective and highly potent neuropeptide Y (NPY) Y2 receptor antagonist with an IC₅₀ value of 19 nM.</p> <p>Purity: ≥99.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg</p>






<p>CYM2503</p> <p style="text-align: right;">Cat. No.: HY-123671</p>	<p>FR252384</p> <p style="text-align: right;">Cat. No.: HY-U00335</p>
<p>CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>FR252384 is a neuropeptide Y-Y5 receptor antagonist, with an IC_{50} of 2.3 nM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Galanin (1-16), mouse, porcine, rat</p> <p style="text-align: right;">Cat. No.: HY-P1578</p>	<p>Galanin (1-16), mouse, porcine, rat TFA</p> <p style="text-align: right;">Cat. No.: HY-P1578A</p>
<p>Galanin (1-16), mouse, porcine, rat is an agonist of the hippocampal galanin receptor, with a K_d of 3 nM.</p> <p style="text-align: right;">GWTLNSAGYLLGPHAI</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Galanin (1-16), mouse, porcine, rat (TFA) is an agonist of the hippocampal galanin receptor, with a K_d of 3 nM.</p> <p style="text-align: right;">GWTLNSAGYLLGPHAI (TFA salt)</p> <p>Purity: 99.39% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>
<p>Galanin (1-29)(rat, mouse)</p> <p style="text-align: right;">Cat. No.: HY-P1132</p>	<p>Galanin (1-29)(rat, mouse) TFA</p> <p style="text-align: right;">Cat. No.: HY-P1132A</p>
<p>Galanin (1-29)(rat, mouse) is a non-selective galanin receptor agonist, with K_s of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3 respectively. Anticonvulsant effect.</p> <p style="text-align: right;">GWTLNSAGYLLGPHAIQDNRHSFSDKHGLT-NH₂</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with K_s of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect.</p> <p style="text-align: right;">GWTLNSAGYLLGPHAIQDNRHSFSDKHGLT-NH₂ (TFA salt)</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Galanin (1-30), human</p> <p style="text-align: right;">Cat. No.: HY-P1127</p>	<p>Galanin Receptor Ligand M35</p> <p style="text-align: right;">Cat. No.: HY-P1840</p>
<p>Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with K_s of both 1 nM.</p> <p style="text-align: right;">GWTLNSAGYLLGPHAVGNHRHSFSDKHGLT-S</p> <p>Purity: 99.11% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>	<p>Galanin Receptor Ligand M35 is a high-affinity ligand and antagonist of galanin receptor ($K_d=0.1$ nM). Galanin Receptor Ligand M35 exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.</p> <p style="text-align: right;">GWTLNSAGYLLGPPPGFSPFR-NH₂</p> <p>Purity: 99.65% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>Galanin Receptor Ligand M35 TFA</p> <p style="text-align: right;">Cat. No.: HY-P1840A</p>	<p>Galantide</p> <p style="text-align: right;">Cat. No.: HY-P0262</p>
<p>Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of galanin receptor ($K_d=0.1$ nM). Galanin Receptor Ligand M35 TFA exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.</p> <p style="text-align: right;">GWTLNSAGYLLGPPPGFSPFR-NH₂ (TFA salt)</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites ($K_b < 0.1$ nM and ~6 nM) in the rat hypothalamus.</p> <p style="text-align: right;">GWTLNSAGYLLGQQQFGLM-NH₂</p> <p>Purity: 99.27% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>

<p>Galnon</p> <p style="text-align: right;">Cat. No.: HY-103536</p> <p>Galnon is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with K_is of 11.7 and 34.1 μM respectively. Galnon exhibits anticonvulsant and anxiolytic effects.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>GR231118 (1229U91; GW1229)</p> <p style="text-align: right;">Cat. No.: HY-P1321</p> <p>GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent, competitive and relative selective antagonist of human neuropeptide Y Y receptor with a pK_i of 10.4.</p>  <p><small>Sequence 1:IEP-(Dpr)-YRLRY-NH₂; Sequence 1:IEP-(Dpr)-YRLRY-NH₂; (Amide bridge:Glu₂-Dpr₄-Dpr₄-Glu₂)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>GR231118 TFA (1229U91 TFA; GW1229 TFA)</p> <p style="text-align: right;">Cat. No.: HY-P1321A</p> <p>GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent, competitive and relative selective antagonist of human neuropeptide YY receptor with a pK_i of 10.4.</p>  <p><small>Sequence 1:IEP-(Dpr)-YRLRY-NH₂; Sequence 1:IEP-(Dpr)-YRLRY-NH₂; (Amide bridge:Glu₂-Dpr₂-Dpr₄-Glu₂) (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HT-2157 (SNAP 37889)</p> <p style="text-align: right;">Cat. No.: HY-100717</p> <p>HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of galanin-3 receptor (Gal₃).</p>  <p>Purity: ≥98.0% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>JNJ-31020028</p> <p style="text-align: right;">Cat. No.: HY-14450</p> <p>JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity (pIC_{50}=8.07, human; pIC_{50}=8.22 rat); >100-fold selective versus human Y1/Y4/Y5 receptors.</p>  <p>Purity: 98.62% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>JNJ-5207787</p> <p style="text-align: right;">Cat. No.: HY-107732</p> <p>JNJ-5207787 is a nonpeptidic, selective and penetrate the blood-brain barrier neuropeptide Y Y₂ receptor (Y₂) antagonist. JNJ-5207787 inhibits the binding of peptide YY (PYY) with pIC_{50}s of 7.0 and 7.1 for human Y₂ receptor and rat Y₂ receptor, respectively.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>L 152804</p> <p style="text-align: right;">Cat. No.: HY-107734</p> <p>L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a K_i of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.</p>  <p>Purity: 99.73% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Lu AA33810</p> <p style="text-align: right;">Cat. No.: HY-107729</p> <p>Lu AA33810 is a potent and selective antagonist of neuropeptide Y5 receptor with a K_i of 1.5 nM for the human receptor. Lu AA33810 exhibits antianxiolytic-like and antidepressant-like effects.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>M1145</p> <p style="text-align: right;">Cat. No.: HY-P1135</p> <p>M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM).</p>  <p><small>RGRGNWTLNSAGYLGGVLPFPALALA-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>M1145 TFA</p> <p style="text-align: right;">Cat. No.: HY-P1135A</p> <p>M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM).</p>  <p><small>RGRGNWTLNSAGYLGGVLPFPALALA-NH₂ (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>M40</p> <p style="text-align: right;">Cat. No.: HY-P1025</p>	<p>M617</p> <p style="text-align: right;">Cat. No.: HY-P1131</p>
<p>M40 is a potent, non-selective galanin receptor antagonist.</p> <p style="text-align: right;">GWTLSAGYLLGPPPALALA-NH₂</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 µg, 1 mg, 5 mg, 10 mg</p>	<p>M617 is a selective galanin receptor 1 (GAL1) agonist, with K_s of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.</p> <p style="text-align: right;">GWTLSAGYLLGPOPPGFSFR-NH₂</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>MK-0557</p> <p style="text-align: right;">Cat. No.: HY-15411</p>	<p>Neuropeptide S(Mouse)</p> <p style="text-align: right;">Cat. No.: HY-P1437</p>
<p>MK-0557 is a highly selective, orally available neuropeptide Y5 receptor antagonist with a K_i of 1.6 nM.</p> <p style="text-align: right;"></p> <p>Purity: 99.76%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p>	<p>Neuropeptide S (Mouse) is a bioactive peptide. Neuropeptide S (Mouse), as a neurotransmitter/neuromodulator of 20 amino acids, can be used for the research of arousal, anxiety, locomotion, feeding behaviors, memory and drug addiction.</p> <p style="text-align: right;">SFRNGVSGGAKKTSFRRAKQ</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Neuropeptide S(Mouse) TFA</p> <p style="text-align: right;">Cat. No.: HY-P1437A</p>	<p>Neuropeptide S(Rat)</p> <p style="text-align: right;">Cat. No.: HY-P1438</p>
<p>Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice.</p> <p style="text-align: right;">SFRNGVSGGAKKTSFRRAKQ (TFA salt)</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Neuropeptide S (Rat) is an endogenous ligand of a previously orphan G-protein-coupled receptor now named NPS receptor. Neuropeptide S (Rat) can be used for the research of nervous system disease.</p> <p style="text-align: right;">SFRNGVSGVKKTSFRRAKQ</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Neuropeptide S(Rat) TFA</p> <p style="text-align: right;">Cat. No.: HY-P1438A</p>	<p>Neuropeptide SF(mouse, rat)</p> <p style="text-align: right;">Cat. No.: HY-P1249</p>
<p>Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC₅₀=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.</p> <p style="text-align: right;">SFRNGVSGVKKTSFRRAKQ (TFA salt)</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Neuropeptide SF (mouse, rat) is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively.</p> <p style="text-align: right;"></p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Neuropeptide SF(mouse, rat) TFA</p> <p style="text-align: right;">Cat. No.: HY-P1249A</p>	<p>Neuropeptide Y (13-36), amide, human</p> <p style="text-align: right;">Cat. No.: HY-P1480</p>
<p>Neuropeptide SF (mouse, rat) TFA is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively.</p> <p style="text-align: right;"></p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Neuropeptide Y (13-36), amide, human is a selective neuropeptide Y₂ receptor agonist.</p> <p style="text-align: right;">PAEDMARYYSALRHYINLITRQRY-NH₂</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 µg, 1 mg, 5 mg</p>

<p>Neuropeptide Y (22-36)</p> <p style="text-align: right;">Cat. No.: HY-P1818</p>	<p>Neuropeptide Y (3-36) (human, rat)</p> <p style="text-align: right;">Cat. No.: HY-P2543</p>
<p>Neuropeptide Y (22-36), a 15 amino acid peptide, is a fragment of Neuropeptide Y. Neuropeptide Y (22-36) acts on Y₂ receptor and retains subnanomolar affinity for the Y₂ receptor.</p> <p style="text-align: right;">SALRHYINLITRQRY-NH₂</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Neuropeptide Y (3-36) (human, rat), a neuropeptide Y (NPY) metabolite formed from dipeptidyl peptidase-4 (DPP4), is a selective Y₂ receptor agonist. Neuropeptide Y (3-36) (human, rat) is a NPY metabolite formed from dipeptidyl peptidase-4 (DPP4).</p> <p style="text-align: right;">SKPSPNPGEDAPAEEDMARIYYSALRHYINLITRQRY-NH₂</p> <p>Purity: 95.28% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>Neuropeptide Y (human)</p> <p style="text-align: right;">Cat. No.: HY-P0198</p>	<p>Neuropeptide Y (human) (TFA)</p> <p style="text-align: right;">Cat. No.: HY-P0198A</p>
<p>Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.</p> <p style="text-align: right;">YPSKPNPGEDAPAEEDMARIYYSALRHYINLITRQRY-NH₂</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.</p> <p style="text-align: right;">YPSKPNPGEDAPAEEDMARIYYSALRHYINLITRQRY-NH₂·TFA·4H₂O</p> <p>Purity: 98.84% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Neuropeptide Y Y1 receptor antagonist 1</p> <p style="text-align: right;">Cat. No.: HY-144603</p>	<p>Neuropeptide Y(29-64)</p> <p style="text-align: right;">Cat. No.: HY-P1601</p>
<p>Neuropeptide Y Y1 receptor antagonist 1 (compound 39), a fluorescent probe, is a potent antagonist of neuropeptide Y Y₁ receptor (Y₁R), with a K_i of 0.19 nM.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Neuropeptide Y(29-64) is a 36 amino acid peptide, a fragment of Neuropeptide Y.</p> <p style="text-align: right;">YPSKPNPGEDAPAEEDMARIYYSALRHYINLITRQRY</p> <p>Purity: 99.47% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pancreatic Polypeptide, bovine</p> <p style="text-align: right;">Cat. No.: HY-P1537</p>	<p>Pancreatic Polypeptide, human (Human pancreatic polypeptide)</p> <p style="text-align: right;">Cat. No.: HY-P0199</p>
<p>Pancreatic Polypeptide, bovine, a 36-amino acid, straight chain polypeptide derived primarily from the pancreas, inhibits secretin- and cholecystokinin-stimulated pancreatic secretion; Pancreatic Polypeptide, bovine acts as an agonist of NPY receptor, with high affinity at NPYR4.</p> <p style="text-align: right;">APLEPVPQGNATPFGDMQYAAELRHYINLITRQRY-NH₂</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>	<p>Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y₄/Y₅ receptor agonist.</p> <p style="text-align: right;">APLEPVPQGNATPFGDMQYAAELRHYINLITRQRY-NH₂</p> <p>Purity: 99.91% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>
<p>Pancreatic Polypeptide, rat (Rat pancreatic polypeptide)</p> <p style="text-align: right;">Cat. No.: HY-P1532</p>	<p>Peptide YY (PYY) (3-36), Human</p> <p style="text-align: right;">Cat. No.: HY-P10000</p>
<p>Pancreatic Polypeptide, rat is an agonist of NPY receptor, with high affinity at NPYR4.</p> <p style="text-align: right;">APLEPVPQGNATPFGDMQYAAELRHYINLITRQRY-NH₂</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>	<p>Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y₂ receptor agonist, is a powerful inhibitor of intestinal secretion.</p> <p style="text-align: right;">KPEAPGSDAPEELNRYYSALRHYINLITRQRY-NH₂</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Peptide YY (PYY) (3-36), porcine</p> <p>Cat. No.: HY-P1021</p>	<p>Peptide YY (PYY) (3-36), porcine TFA</p> <p>Cat. No.: HY-P1021A</p>
<p>Peptide YY (PYY) (3-36), porcine is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.</p> <p><small>AKPEAFGEDASPEELSRYYASLRHYNLVYTRQRY-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Peptide YY (PYY) (3-36), porcine TFA is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.</p> <p><small>AKPEAFGEDASPEELSRYYASLRHYNLVYTRQRY-NH₂ (TFA salt)</small></p> <p>Purity: 99.21% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>Peptide YY (PYY), human</p> <p>Cat. No.: HY-P1514</p> <p>Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.</p> <p><small>YKPKAFPGEDASPEELSRYYASLRHYNLVYTRQRY-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 µg</p>	<p>RF9</p> <p>Cat. No.: HY-107382</p> <p>RF9 is a potent and selective Neuropeptide FF receptor antagonist, with K_i values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.</p>  <p>Purity: 98.66% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg</p>
<p>RF9 hydrochloride</p> <p>Cat. No.: HY-107382A</p> <p>RF9 hydrochloride is a potent and selective Neuropeptide FF receptor antagonist, with K_i values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.</p>  <p>Purity: 99.48% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>RFRP-1(human)</p> <p>Cat. No.: HY-P1428</p> <p>RFRP-1(human) is a gonadotropin-inhibitory hormone (GnIH) homolog. RFRP-1(human) targets human gonadotropin-releasing hormone (GnRH) neurons and gonadotropes and potently inhibits gonadotropin.</p> <p><small>MPHSFANLPLRF-NH₂</small></p> <p>Purity: 99.32% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>RFRP-1(human) TFA</p> <p>Cat. No.: HY-P1428A</p> <p>RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC_{50} values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes.</p> <p><small>MPHSFANLPLRF-NH₂ (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>RFRP-3(human) (Neuropeptide VF(124-131)(human))</p> <p>Cat. No.: HY-P1250</p> <p>RFRP-3 (Neuropeptide VF(124-131))(human), a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca^{2+} mobilization.</p>  <p>Purity: 98.51% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>RFRP-3(human) TFA (Neuropeptide VF(124-131)(human) TFA)</p> <p>Cat. No.: HY-P1250A</p> <p>RFRP-3 (Neuropeptide VF(124-131))(human) TFA, a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca^{2+} mobilization.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>RTI-118</p> <p>Cat. No.: HY-111308</p> <p>RTI-118 is a novel small-molecule neuropeptide S receptor (NPSR) antagonist. RTI-118 can relieve drug addiction including selectively decrease cocaine self-administration.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>S 25585</p> <p>Cat. No.: HY-107728</p>	<p>SF 11</p> <p>Cat. No.: HY-107731</p>
<p>S 25585 is a potent and selective neuropeptide Y (NPY) Y5 receptor antagonist. S 25585 reduces food intake but not through blockade of the NPY Y5 receptor.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>SF 11 is a potent and brain penetrant neuropeptide Y Y2 receptor antagonist ($IC_{50}=199$ nM). Antidepressant-like activity.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>SHA 68</p> <p>Cat. No.: HY-108625</p>	<p>Spexin (Neuropeptide Q)</p> <p>Cat. No.: HY-P1723</p>
<p>SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC_{50}s of 22.0 and 23.8 nM for NPSR Asn¹⁰⁷ and NPSR Ile¹⁰⁷, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia.</p>  <p>Purity: 98.05%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Spexin is a conserved peptide plays roles of neurotransmitter/neuromodulator and endocrine factor. Spexin peptide contains numerous aromatic amino acids and is probably amidated.</p> <p>NWTPQAMLYLKGAQ-NH₂</p> <p>Purity: 98.10%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Spexin TFA (Neuropeptide Q TFA)</p> <p>Cat. No.: HY-P1723A</p>	<p>Velneperit (S2367)</p> <p>Cat. No.: HY-14423</p>
<p>Spexin TFA is a potent galanin receptor 2/3 (GAL2/GAL3) agonist (EC_{50} values are 45.7 and 112.2 nM, respectively). Spexin TFA exhibits no significant activity at galanin receptor 1.</p> <p>NWTPQAMLYLKGAQ-NH₂ (TFA salt)</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist. Target: neuropeptide Y receptor Velneperit (S-2367) is a once-daily, oral, centrally acting, small molecule neuropeptide Y (NPY) Y5 receptor antagonist.</p>  <p>Purity: 99.50%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Y1R probe-1</p> <p>Cat. No.: HY-145837</p>	<p>[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide</p> <p>Cat. No.: HY-P1324</p>
<p>Y1R probe-1 (Compound 39) is a high-affinity fluorescence probe for the Neuropeptide Y Y1 Receptor. Y1R probe-1 has the potential for the research of cancer disease.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y₅ receptor agonist with an IC_{50} of 0.24 nM for binding to the hY₅ receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake.</p> <p>GPGPTFPGNATPCQATYALRYFYMWABRQRYNH₂</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic polypeptide TFA</p> <p>Cat. No.: HY-P1324A</p>	<p>[D-Arg25]-Neuropeptide Y (human)</p> <p>Cat. No.: HY-P0198B</p>
<p>[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y₅ receptor agonist with an IC_{50} of 0.24 nM for binding to the hY₅ receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake.</p> <p>GPGPTFPGNATPCQATYALRYFYMWABRQRYNH₂ (TFA salt)</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y₁ receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.</p> <p>YPSKPKGSDGAPAEEMARYYSAL[D-Arg]-HYHLLTRQRYNH₂</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

[D-Trp34]-Neuropeptide Y

Cat. No.: HY-P1322

[D-Trp34]-Neuropeptide Y is a potent and selective **neuropeptide Y (NPY) Y₅ receptor** agonist.

[D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y₁, Y₂, Y₄ and Y₆ receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats.

YPSKPNFQEDAFADLQARYSALRYHLLTR(D-Trp)RYNH₄

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg

[D-Trp34]-Neuropeptide Y TFA

Cat. No.: HY-P1322A

[D-Trp34]-Neuropeptide Y TFA is a potent and selective **neuropeptide Y (NPY) Y₅ receptor** agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y₁, Y₂, Y₄ and Y₆ receptors.

YPSKPNFQEDAFADLQARYSALRYHLLTR(D-Trp)RYNH₄(TFA)NH₂

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg

[Leu31,Pro34]-Neuropeptide Y (porcine)

Cat. No.: HY-P0208

[Leu31,Pro34]-Neuropeptide Y (porcine), a Neuropeptide Y (NPY) analog, is a selective **NPY Y₁ receptor** agonist. [Leu31,Pro34]-Neuropeptide Y (porcine) exhibits anxiolytic effects.

YPSKPNFQEDAFADLQARYSALRYHLLTRPPY-NH₂

Purity: 98.66%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg

[Leu31,Pro34]-Neuropeptide Y(human, rat)

Cat. No.: HY-P1323

[Leu31,Pro34]-Neuropeptide Y(human, rat) is a specific **neuropeptide Y Y₁ receptor** agonist. [Leu31,Pro34]-Neuropeptide Y(human, rat) also activates Y₄, Y₅. [Leu31,Pro34]-Neuropeptide Y(human, rat) can increase blood pressure in anesthetized rats and increases food intake.

YPSKPNFQEDAFADLQARYSALRYHLLTRPPY-NH₂

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg

[Leu31,Pro34]-Neuropeptide Y(human, rat) TFA

Cat. No.: HY-P1323A

[Leu31,Pro34]-Neuropeptide Y(human, rat) TFA is a specific **neuropeptide Y Y₁ receptor** agonist. [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA also activates Y₄, Y₅. [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA can increase blood pressure in anesthetized rats and increases food intake.

YPSKPNFQEDAFADLQARYSALRYHLLTRPPY-NH₂(TFA)NH₂

Purity: 99.38%

Clinical Data: No Development Reported

Size: 5 mg, 10 mg